7 results
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
IDSA - Prophylaxis ... Pneumocystis pneumonia (PCP ... Infections #OIs #HIVAIDS ... #IDSA #management ... #pharmacology
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
IDSA - Prophylaxis ... Pneumocystis pneumonia (PCP ... Infections #OIs #HIVAIDS ... #IDSA #management ... #pharmacology
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
IDSA Recommendations ... #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Prevention and Treatment of Pneumocystis Pneumonia (PCP) in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
IDSA Recommendations ... Pneumocystis Pneumonia (PCP ... #PCP #PJP #jiroveci ... opportunistic #infections #HIVAIDS ... #management #pharmacology
Differentiation Syndrome in APML
Epidemiology:
 • Incidence: common in APL (2-48% depending on the study)
 • Triggers:
Differentiation Syndrome ... Triggers: ATRA treatment ... fluid overload, PCC ... APML #diagnosis #management ... #hematology #oncology
Aplastic Anemia - Overview

Who?
• M = F
• 3 peaks:	1) Childhood	2) 15-25 years	3) >60 years

What?
• Aplastic anemia
- β-lactam antibiotics ... aplastic anemia Treatment ... Aplastic #Anemia #oncology ... #hematology #diagnosis ... #management
IDSA Recommendations for Preventing and Treating HHV-8 Diseases—Kaposi Sarcoma (KS), Primary Effusion Lymphoma (PEL), Multicentric Castleman’s
IDSA Recommendations ... #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology